News

Researchers Identify Protein That Could Help Further Explore Metabolic and Inflammatory Theories Behind PAH Development

Two theories behind the pathogenesis of pulmonary arterial hypertension (PAH) converge on the protein known as the master transcription factor forkhead box O1 (FoxO1). Leaders in the field of PAH research are excited about the notion that addressing master transcription factors may integrate the metabolic and inflammatory theories behind PAH,…

PHA Supports PH Research With Over $15 Million In Grants

The Pulmonary Hypertension Association (PHA), the US’s leading fundraising and advocacy group for funding scientific research to discover new ways to prevent and cure pulmonary hypertension (PH), will celebrate its 25th Anniversary in 2016. In celebration of that milestone and to continue the fight against the disease, the PHA has announced that…

HRCT Predicts Lung Function Decline in SSc Patients

Patients with systemic sclerosis (SSc) are at an increased risk for mortality due to concurrent pulmonary hypertension or interstitial lung disease. While pulmonary hypertension results in right-sided heart failure, interstitial lung disease results in extensive lung fibrosis. It may be possible to test for lung scarring using high resolution computed…

Bayer Finds Pulmonary Embolism Patients Are Not Adequately Screened for PH

Representatives from Bayer HealthCare Pharmaceuticals presented findings at the American Thoracic Society’s (ATS) 2015 International Conference that suggest pulmonary hypertension is more prevalent in patients with pulmonary embolisms than was previously thought. Although the rate may be at least twice as high as previously identified, many patients do not undergo the…

Celsion Corporation Announces TheraSilence Technology Effective in Model of Potential Severe Occlusive PAH Treatment

Celsion Corporation, an oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies, recently announced an abstract publication in the Journal of Controlled Release. The abstract summarizes results from a preclinical trial which confirmed the effective…

Mitral Valve Surgery Identified As Potential Treatment For PAH Secondary to Mitral Valve Disease

In a recent study entitled “An excellent result of surgical treatment in patients with severe pulmonary arterial hypertension following mitral valve disease,” authors analyzed recent outcomes and mortality rates for patients with pulmonary arterial hypertension who underwent mitral valve surgery. They observed a significant decrease in the number of deaths…


A Conversation With Rare Disease Advocates